BELATACEPT COMPARED WITH CYCLOSPORINE IN RENAL ALLOGRAFT RECIPIENTS OF EXTENDED CRITERIA DONOR KIDNEYS: 3-YEAR OUTCOMES FROM THE PHASE III BENEFIT-EXT TRIAL

被引：0
作者：
Medina Pestana, J. [1 ]
Grinyo, J. [2 ]
Vanrenterghem, Y. [3 ]
Becker, T. [4 ]
Florman, S. [5 ]
Lang, P. [6 ]
Rial, M. del C. [7 ]
Schnitzler, M. [8 ]
Duan, T. [9 ]
Block, A. [9 ]
Durrbach, A. [10 ]
机构：
[1] Hosp Rim & Hipertensao, Sao Paulo, Brazil
[2] Univ Hosp Bellvitge, Barcelona, Spain
[3] Univ Hosp Leuven, Louvain, Belgium
[4] Hannover Med Sch, D-30623 Hannover, Germany
[5] Mt Sinai Med Ctr, New York, NY 10029 USA
[6] Hop Henri Mondor, F-94010 Creteil, France
[7] Inst Nefrol, Buenos Aires, DF, Argentina
[8] St Louis Univ, St Louis, MO 63103 USA
[9] Bristol Myers Squibb Co, Princeton, NJ USA
[10] Hop Bicetre, Le Kremlin Bicetre, France
来源：
TRANSPLANT INTERNATIONAL | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [41] Three-Year Outcomes from BENEFIT: A Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients
    Vincenti, F.
    Larsen, C. P.
    Alberu, J.
    Garcia, V. D.
    Rostaing, L.
    Rice, K.
    Schnitzler, M.
    Xing, J.
    Agarwal, M.
    Charpentier, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 99 - 99
  • [42] THREE-YEAR OUTCOMES FROM BENEFIT: A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS
    Vincenti, F.
    Larsen, C.
    Alberu, J.
    Garcia, V.
    Rostaing, L.
    Rice, K.
    Schnitzler, M.
    Xing, J.
    Agarwal, M.
    Charpentier, B.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 21 - 21
  • [43] THREE-YEAR OUTCOMES FROM BENEFIT: A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS
    Vincenti, Flavio
    Larsen, Christian P.
    Alberu, Josephina
    Garcia, Valter D.
    Rostaing, Lionel
    Rice, Kim
    Schnitzler, Mark
    Xing, Jun
    Agarwal, Mamta
    Charpentier, Bernard
    TRANSPLANT INTERNATIONAL, 2011, 24 : 68 - 68
  • [44] Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies
    Larsen, Christian P.
    Grinyo, Josep
    Medina-Pestana, Jose
    Vanrenterghem, Yves
    Vincenti, Flavio
    Breshahan, Barbara
    Campistol, Josep M.
    Florman, Sander
    del Carmen Rial, Maria
    Kamar, Nassim
    Block, Alan
    Di Russo, Gregory
    Lin, Chen-Sheng
    Garg, Pushkal
    Charpentier, Bernard
    TRANSPLANTATION, 2010, 90 (12) : 1528 - 1535
  • [45] De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies
    Bray, R. A.
    Gebel, H. M.
    Townsend, R.
    Roberts, M. E.
    Polinsky, M.
    Yang, L.
    Meier-Kriesche, H. -U.
    Larsen, C. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (07) : 1783 - 1789
  • [46] Four-Year Outcomes in Black/African American Kidney Transplant Recipients from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies.
    Florman, S.
    Rice, K.
    Chan, L.
    Steinberg, S.
    Pearson, T.
    Duan, T.
    Argawal, M.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 404 - 404
  • [47] PRIMARY OUTCOMES FROM A RANDOMIZED, PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS (BENEFIT STUDY)
    Vincenti, F.
    Grinyo, J. M.
    Charpentier, B.
    Medina-Pestana, J. D.
    Rostaing, L.
    Vanrenterghem, Y.
    Di Russo, G. B.
    Garg, P.
    Lin, C. -S.
    Larsen, C.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 89 - 89
  • [48] Primary Outcomes from a Randomized, Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)
    Pearson, Thomas
    Vincenti, Flavio
    Grinyo, Josep
    Charpentier, Bernard
    Pestana, Jose Medina
    Rostaing, Lionel
    Vanrenterghem, Yves
    Di Russo, Gregory
    Garg, Pushkal
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 6 - 6
  • [49] Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study).
    Vincenti, F.
    Grinyo, J. M.
    Charpentier, B.
    Medina-Pestana, J. D.
    Rostaing, L.
    Vanrenterghem, Y.
    Di Russo, G. B.
    Garg, P.
    Lin, C. -S.
    Larsen, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 191 - 192
  • [50] Impact on 1 and 3-year renal allograft survival with the use of unos defined expanded donor criteria kidney grafts. SRT data comparison of a single institution vs national outcomes.
    Campos, L
    Philosophe, B
    David, LB
    Eugene, SJ
    Clarence, FF
    Bartlett, ST
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 396 - 396
12345